Search Result

Results for "

ischaemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Kinase (1) Adrenergic Receptor (2) Akt (1) Apoptosis (1) Calcium Channel (1) Caspase (1) Cyclophilin (1) Dynamin (2) Endogenous Metabolite (5) GlyT (1) iGluR (4) Isotope-Labeled Compounds (1) NF-κB (1) Potassium Channel (6) Sigma Receptor (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (11) Endocrinology (1) Inflammation/Immunology (4) Metabolic Disease (8) Neurological Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101101

L-701252	iGluR	Neurological Disease
L-701252 is a potent antagonist of glycine site NMDA receptor with an IC₅₀ of 420 nM. L-701252 provides a small degree of neuroprotection in global cerebral ischaemia .

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Endogenous Metabolite Potassium Channel	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-148327

AK-IN-1	Adenosine Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
AK-IN-1 (compound 4072-2732) is an adenosine kinase (AK) inhibitor that is competitive for adenosine (Ado) but not for ATP. AK-IN-1 inhibits 86%, 87% and 89% of AK activity at concentrations of 2, 4 and 10 µM, respectively. AK-IN-1 has good potential for research in many disease areas, including ischaemia, inflammation and seizures .

HY-W018026

Oxfenicine L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842	Others	Metabolic Disease
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acid in heart. Oxfenicine protects heart from necrotic tissue damage during ischaemia .

HY-131041

Ned-K	Calcium Channel	Cardiovascular Disease
Ned-K is a nicotinic acid adenine dinucleotide phosphate (NAADP) antagonist. Ned-K is effective at dampening simulated ischaemia and reperfusion (sIR)-induced Ca ²⁺ oscillations in cardiomyocytes .

HY-N6634

Araloside C	Others	Others
Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury .

HY-155941

5-Hydroxydecanoic acid	Potassium Channel	Neurological Disease
5-Hydroxydecanoic acid (5-HD） is a K_ATP channel antagonist，which has the effect of blocking the K K_ATP channel only during ischaemia by competing with the ATP binding site and does not affect pancreatic K_ATP channels .

HY-106039

LY 215490	iGluR	Neurological Disease
LY 215490 is a selective, competitive AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC₅₀ values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .

HY-117699

Fluanisone	Others	Neurological Disease
Fluanisone has potent sedative effect in vivo. Fluanisone can be used to study schizophrenia .

HY-15068

NBQX Maximum Cited Publications 10 Publications Verification FG9202	iGluR	Neurological Disease
NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .

HY-15068A

NBQX disodium Maximum Cited Publications 10 Publications Verification FG9202 disodium	iGluR	Neurological Disease
NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .

HY-131370B

Intralipid 20%	Others	Cancer
Intralipid 20% is a safe fat emulsion that can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .

HY-107526

(Rac)-ALX 5407 (Rac)-NFPS	GlyT	Neurological Disease
NFPS is a selective, non-competitive glycine transporter-1 (GlyT1) inhibitor with IC₅₀s of 2.8 nM and 9.8 nM for hGlyT1 and rGlyT1, respectively . NFPS exerts neuroprotection via glyR alpha1 subunit in the rat model of transient focal cerebral ischaemia and reperfusion .

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride	Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-113147S1

L-Palmitoylcarnitine-d9	Isotope-Labeled Compounds Potassium Channel Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-108515

(+)-Igmesine hydrochloride JO1784	Sigma Receptor	Neurological Disease
(+)-Igmesine hydrochloride (JO1784) is an orally active and selective σ receptor ligand with neuroprotective and anti-amnesic activities .

HY-107571

VULM 1457	Acyltransferase	Cardiovascular Disease Metabolic Disease
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .

HY-121012

(rac)-AG-205	NF-κB Akt	Endocrinology
(rac)-AG-205 is a potent inhibitor of progesterone receptor membrane component 1 (Pgrmc1) that induces genes involved in sterol synthesis, including the INSIG1 protein, which forms a complex with PGRMC1. (rac)-AG-205 prevents neuronal resistance to hypoxic ischaemia by blocking NF-kB signalling and activation of the BDNF/PI3K/AKT pathway .

HY-152086

DRP1i27	Dynamin	Cardiovascular Disease
DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-101337

Imiloxan RS 21361 free base	Adrenergic Receptor	Metabolic Disease Inflammation/Immunology
Imiloxan is a potent and selective alpha 2B-adrenoceptor antagonist. Imiloxan has the potential for acute kidney injury research .

HY-152086A

DRP1i27 dihydrochloride	Dynamin	Cardiovascular Disease
DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .

HY-157088

C105SR	Caspase Apoptosis Cyclophilin	Others
C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC ₅₀ of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .

HY-121166

Levobetaxolol (S)-Betaxolol	Adrenergic Receptor	Others
Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC₅₀ values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .

Cat. No.	Product Name	Target	Research Area

HY-P3211A

Nangibotide TFA 3 Publications Verification LR12 TFA	Peptides	Cardiovascular Disease Inflammation/Immunology
Nangibotide TFA is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide TFA can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia-reperfusion .

HY-P3211

Nangibotide LR12	Peptides	Inflammation/Immunology
Nangibotide is a TREM-1 receptor inhibitor that can modulate innate immune response. Nangibotide can reduce systemic and in situ inflammatory reaction in rodent models of myocardial ischaemia‐reperfusion .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113147A

L-Palmitoylcarnitine chloride 1 Publications Verification	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147

L-Palmitoylcarnitine 1 Publications Verification	Cardiovascular Disease Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Potassium Channel Endogenous Metabolite
L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-113147B

L-Palmitoylcarnitine TFA 1 Publications Verification	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Potassium Channel
L-Palmitoylcarnitine TFA, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine TFA inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

HY-N6634

Araloside C	Triterpenes Classification of Application Fields Terpenoids Source classification Other Diseases Aralia elata (Miq.) Seem. Plants Disease Research Fields Araliaceae	Others
Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury .

Cat. No.	Product Name	Chemical Structure

HY-113147AS

L-Palmitoylcarnitine-d3 hydrochloride
L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

L-Palmitoylcarnitine-d3 hydrochloride

L-Palmitoylcarnitine-d₃ (hydrochloride) is the deuterium labeled L-Palmitoylcarnitine hydrochloride. L-Palmitoylcarnitine hydrochloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine hydrochloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].

HY-113147S1

L-Palmitoylcarnitine-d9
L-Palmitoylcarnitine-d₉ is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits K_ATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks